{"nctId":"NCT02589275","briefTitle":"A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients","startDateStruct":{"date":"2015-08-04","type":"ACTUAL"},"conditions":["Primary Fibromyalgia"],"count":375,"armGroups":[{"label":"TNX-102 SL Tablet 2.8 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TNX-102 SL Tablet 2.8 mg"]}],"interventions":[{"name":"TNX-102 SL Tablet 2.8 mg","otherNames":["cyclobenzaprine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient met all prior inclusion and exclusion requirements for study F301 or F302 originally, and has had no intervening medical conditions, increased suicidal ideation, or requirements for concomitant medications that preclude exposure to TNX-102 SL or enrollment in the extension study.\n* The patient completed expected dosing in F301 or F302 defined as taking study medication up to Week 12, with at least 70% compliance with medication usage (based on overall drug accountability reconciliation at the end of the F301 or F302 lead-in study) and no major protocol deviations.\n* The patient has provided written informed consent to participate in this extension protocol.\n\nExclusion Criteria:\n\n* None","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Newly Emergent Adverse Events","description":"The number of patients with at least one adverse event which began after the first dose of TNX-102 SL in this open-label extension study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":170},"commonTop":["Hypoaesthesia Oral","Product Taste Abnormal","Parasthesia Oral","Tongue Discomfort"]}}}